Shanghai Kehua Bio-Engineering Co.,Ltd (SHE:002022)

Market Cap	3.07B +6.4%
Revenue (ttm)	1.60B -14.6%
Net Income	-750.99M
EPS	-1.47
Shares Out	500.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,507,600
Average Volume	17,557,675
Open	6.15
Previous Close	6.14
Day's Range	6.11 - 6.25
52-Week Range	4.88 - 8.45
Beta	0.52
RSI	43.89
Earnings Date	Apr 17, 2026

About SHE:002022

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reag...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1981
• Employees: 2,033
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002022

Financial Performance

In 2024, SHE:002022's revenue was 1.76 billion, a decrease of -27.55% compared to the previous year's 2.43 billion. Losses were -640.60 million, 173.7% more than in 2023.